



**GlaxoSmithKline UK Ltd**

Stockley Park West  
Uxbridge  
Middlesex  
UB11 1BT

Tel. +44 (0)20 8990 9000  
Fax. +44 (0)20 8990 4321  
www.gsk.com

25th June 2018

## **GLAXOSMITHKLINE SAFETY ADVISORY**

### **Reminder letter regarding the discontinuation of Eperzan ▼ (albiglutide) 1st July 2018**

#### **Subject: Final reminder of Discontinuation of EPERZAN (albiglutide)**

Dear Pharmacist,

Following prior communication by GSK in September 2017 and February 2018, this is a final targeted reminder letter you you to remind you that GSK will discontinue the commercial sale and availability of Eperzan worldwide. **Commercial supplies will no longer be available in the UK from 1st July 2018.**

#### **You are being sent this**

Please note the following:

#### **Suggested Actions**

- 1: For any remaining patients who are still taking Eperzan, discuss with them or their GP transitioning to an alternative therapy, as soon as possible and prior to end of June 2018
- 2: Do not dispense Eperzan for any new patients.
- 3: Ensure your pharmacy team and the relevant prescriber/s are aware of this information.

## Background and further information

Eperzan ▼ (albiglutide) subcutaneous injections (30 mg and 50 mg) have been licenced in the UK since 2014 for adults with type 2 diabetes mellitus. **This withdrawal is on commercial grounds only, and is not related to efficacy or safety of the medicine.** GSK has also communicated this decision to the EMA and the MHRA.

If you have any questions, please contact the Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT; customercontactuk@gsk.com; Freephone: 0800 221441

For medical information enquiries please email ukmedinfo@gsk.com or call 0800 221 441 (option 4)

Yours sincerely,



Dr Mihaela Ianosev  
Medical Director  
Speciality Care Business Unit, Europe

**Adverse events should be reported. For the UK, reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441**

This letter is not a comprehensive description of the risks with the use of EPERZAN. Please refer to the Summary of Product Characteristics available at <http://www.medicines.org.uk/emc/>

Trade marks are owned by or licensed to the GSK group of companies